An investigation on the late side effects of a combination of two forms of brachytherapy to treat cervical cancer has revealed that the technique delivers higher radiation doses to the tumor without additional treatment-related complications afterwards.
Brachytherapy, with or without external beam radiation, can improve survival in women with inoperable, early stage endometrial cancer.
High-dose-rate (HDR) brachytherapy is typically used as a dose-escalating boost for external beam radiotherapy for prostate cancer; however, some researchers believe it might be close to graduating to a viable monotherapy.
Specific guidance for delivering high dose-rate brachytherapy to improve quality and safety is offered in a new white paper from the American Society for Radiation Oncology (ASTRO).
Long-term outcomes of breast cancer patients receiving adjuvant accelerated partial breast irradiation after breast-conserving surgery show excellent tumor control with minimal late toxicity.
When comparing treatments designed to enable long-term breast preservation for older women with invasive breast cancer, researchers found that those treated with brachytherapy were at higher risk for a later mastectomy.
Brachytherapy treatment was found to be associated with better cause-specific survival and overall survival in women with cervical cancer in a new study.
or women with stage IIIB squamous cervical cancer, cisplatin added to radiotherapy plus high-dose-rate brachytherapy (HDRB) is associated with improved disease-free survival.
Accelerated partial breast irradiation is an option for brachytherapy that can deliver higher doses with better cosmesis for select patients with breast cancer.
A posttreatment assessment of men who underwent treatment for prostate cancer revealed a side effect that has a significant impact on patients.
The breast cancer treatment brachytherapy, heralded for its low complication rates, actually results in more complications than whole-breast radiation 1 year after treatment.
Researchers have identified 12 genetic markers linked with susceptibility for erectile dysfunction after radiotherapy for prostate cancer.
Although brachytherapy has not been considered very effective for high-risk prostate cancer, it reduced disease-specific mortality compared with external beam radiation alone.
Two studies published in International Journal of Radiation Oncology*Biology*Physics indicate that proton therapy is a useful treatment for prostate cancer.
Many women who underwent accelerated partial breast irradiation using brachytherapy were deemed cautionary or unsuitable for the procedure based on guidelines later issued by ASTRO.
Although popular among older women with breast cancer, accelerated partial breast brachytherapy may be less effective and more toxic than standard whole breast irradiation in these patients.
Data presented on the evolving role of radiation therapy in local and regional tumor control at the ASCO 2010 Breast Cancer Symposium, October 1-3, 2010, are reviewed.
Prostate cancer patients who receive the optimum radiation dose on the same day as their brachytherapy implant may have a lower risk of relapse, according to a study conducted by researchers at the University Hospital of Navarre.
Modern radiotherapy achieves cure rates comparable to surgery for early stage prostate cancer and with androgen deprivation therapy, is the optimal treatment for transcasular extension of disease
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|